Th2 Cytokines (Interleukin-5 and -9) Polymorphism Affects the Response to Anti-TNF Treatment in Polish Patients with Ankylosing Spondylitis

• Published in: International journal of molecular sciences 2022-10, Vol.23 (21), p.13177
• Main Authors: Biały, Sylwia, Iwaszko, Milena, Świerkot, Jerzy, Bugaj, Bartosz, Kolossa, Katarzyna, Jeka, Sławomir, Bogunia-Kubik, Katarzyna
• Format: Article
• Language: English
• Subjects: Alleles; Ankylosing spondylitis; anti-TNF; Arthritis; Autoimmune diseases; Chromosomes; Cytokines; Cytokines - genetics; Disease; Genetic diversity; Genotype & phenotype; Genotyping; Health services; Humans; IL5; IL9; Immunology; Inflammation; Inflammatory diseases; Interleukin 5; Interleukin 9; Interleukin-5 - genetics; Interleukin-9 - genetics; Lymphocytes; Lymphocytes T; Nucleotides; Pathogenesis; Patients; Poland; Polymorphism; Polymorphism, Single Nucleotide; Rheumatic diseases; Single-nucleotide polymorphism; Spondylitis, Ankylosing - drug therapy; Spondylitis, Ankylosing - genetics; Spondylitis, Ankylosing - pathology; TNF inhibitors; Tumor necrosis factor; Tumor Necrosis Factor Inhibitors - therapeutic use
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms232113177

Ankylosing spondylitis (AS) is an inflammatory disease that belongs to the spondyloarthritis family. IL-5 and IL-9 belong to the group of Th2 cytokines of anti-inflammatory nature. Polymorphisms in their coding genes have been so far associated with various inflammatory diseases, but there are no reports regarding their involvement in AS pathogenesis to date. The purpose of the study was to investigate relationships between IL5 and IL9 genetic variants with AS susceptibility, clinical parameters as well as response to therapy with TNF inhibitors. In total 170 patients receiving anti-TNF therapy and 218 healthy controls were enrolled in the study. The genotyping of IL5 rs2069812 (A > G) and IL9 rs2069885 (G > A) single nucleotide polymorphisms was performed using the Real-Time PCR method based on LightSNiP kits assays. The present study demonstrated significant relationships between IL5 rs2069812 and IL9 rs2069885 polymorphisms and response to anti-TNF therapy. Presence of the IL5 rs2069812 A allele in patients positively correlated with better response to treatment (p = 0.022). With regard to IL9 rs2069885, patients carrying the A allele displayed better outcomes in anti-TNF therapy (p = 0.046). In addition, IL5 rs2069812 A and IL9 rs2069885 A alleles were associated with lower CRP and VAS values. The obtained results may indicate a significant role for IL-5 and IL-9 in the course of AS and response to anti-TNF therapy.